NEXENTIS TECHNOLOGIES INC. Operating Lease Cost
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Operating Lease Cost of $15.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-31
- NEXENTIS TECHNOLOGIES INC. operating lease, cost for fiscal 2025 was $15.00K, a 63.41% decline from fiscal 2024.
- NEXENTIS TECHNOLOGIES INC. operating lease, cost for fiscal 2024 was $41.00K, a 25.45% decline from fiscal 2023.
- NEXENTIS TECHNOLOGIES INC. operating lease, cost for fiscal 2023 was $55.00K, a 31.68% decline from fiscal 2022.
- NEXENTIS TECHNOLOGIES INC. operating lease, cost for fiscal 2022 was $80.50K, a 106.57% increase from fiscal 2021.
| Period end | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|
| 2025-12-31 | $15.00K 10-K · filed 2026-03-31 | |
| 2024-12-31 | $41.00K 10-K · filed 2026-03-31 | |
| 2023-12-31 | $55.00K 10-K · filed 2025-03-31 | $54.72K 10-K · filed 2024-04-01 |
| 2022-12-31 | $80.50K 10-K · filed 2024-04-01 | |
| 2021-12-31 | $38.97K 10-K · filed 2023-03-27 | |
| 2020-12-31 | $40.97K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |